Investorideas.com newswire, stock news and business news for investors

Tuesday, November 24, 2015

JOIN Investorideas.com for Cyber Monday

JOIN Investorideas.com for Cyber Monday

50% off our annual membership – one year for just $48.50

Get Trading Ideas all year long for just over 0.13 a day!!!

 

 

Find great stocks in your favorite stock sector ... We have built lists of publicly traded stocks in each sector - microcap, small cap, large cap! We get you started... you find the ideas right for you!
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!
Just $48.50 a year

Sign Up Here

What do our Investor Ideas members get?

Exclusive Login access to our Global Stock Directories that are updated each month - thousands of stocks to research by sector...
Stocks listed may include the following stock exchanges: TSX, OTC, NASDAQ, NYSE, ASX, LSE – AIM, LSE – IRELAND, XETRA, FRANKFURT, BERLIN, EURONEXT, CHINA , HONG KONG, TOKYO, PARIS, MILAN, SPAIN, INDIA, MALAYSIA, SINGAPORE, MEXICO, ITALY, ARGENTINA, BRAZIL, TAIWAN, OSLO EXCHANGE (NORWAY), GREECE – ATHENS EXCHANGE, SWITZERLAND
*Due to the nature of the Investor Ideas members content, we do not offer trial memberships, in order to protect the proprietary stock directories. Therefore the membership is not refundable unless an incorrect purchase is made and we are notified immediately following the transaction the same day . Members are reminded the directories are for personal use only and not to be reproduced on other websites. Membership logins are not to be shared with other non- member users! Any violation of this will be taken very seriously.
Stock Directories Disclaimer
Investorideas.com paid stock directories are not guaranteed to be 100 % accurate but we do our best to update the directories and make edits and changes on a regular basis. Our stock directories do not include all publicly traded stocks within the sector but reflect a thorough representation of each sector we follow. All company descriptions are sourced from the company's public information.

About Investorideas.com - Big Ideas for Global Investors

InvestorIdeas.com - digital media global news source, PR and social media in leading sectors.
Sectors we cover include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also recently expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.
Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: http://www.investorideas.com/About/Disclaimer.asp 
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Contact Investorideas.com

800 665 0411

Friday, September 11, 2015

Investorideas.com Announces its First Global ‘Follow the Money’ Contest


Investorideas.com Announces its First Global ‘Follow the Money’ Contest

New York NY- Point Roberts WA–September 11, 2015 -- Investorideas.com (www.investorideas.com), a global investor news source covering leading sectors
announces its first ever ‘Follow the Money’ contest for global investors.

The contest will run from September 15th to October 31st, 2015 and is open to Investor Ideas members. (http://www.investorideas.com/membership/)

Prizes include a ‘Money Suit’ as seen worn by the Investorideas.com Money Team and also by Will Ferrell at the 2013 MTV Movie Awards.  Prizes also include Annual Small Cap Pro Accounts from Investor Hub http://investorshub.advfn.com/ with more prizes to be announced shortly.

The contest will consist of investors picking a stock or stocks they wish to buy within sectors they like and within the time frame of the contest (either real trades or fictional trades). Investors can buy their favorite beverage stock such as Starbucks Corporation (SBUX) from our beverage stock directory, their favorite Yoga Brand like Lululemon Athletica Inc. (LULU) from our LOHAS directory or Ralph Lauren Corporation (RL) from our Luxury Brand stock directory.

This contest gives investors a chance to not only invest in their favorite sectors and companies but also to test their skills against other global investors.  Investorideas.com stock directories feature and include stocks from most global stock exchanges. Key sectors covered include biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks including wine stocks, luxury retail brands, sports stocks and others.







More Info about Small Cap Pro: Small Cap Pro provides online Level 2 quotes for active stock traders. Users receive live Level 2 data for both OTCBB stocks and Pink Sheets. You will be able to use the Level 2 order book to see the buying support and selling pressure. This info will help determine when is a good time to buy or sell the stock. The Level 2 tool is available on the website or in the mobile apps.

This package also provides Level 1 stock quotes for all the web site tools such as monitor watchlists, charts, portfolio, last 100 trades, and toplists. This wide range of access provides live stock quotes everywhere you go. The data is unlimited so you are finally free to explore the world of stocks to your heart's content. Let our tools help you analyze and find the next great stock. Don't miss another great trading opportunity

About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks, sports and entertainment and Latin American stocks.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for our free news alerts

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

To Sponsor the contest with your brand or service call or email

Dawn or Cali

800-665-0411 - Source – www.Investorideas.com





Friday, March 6, 2015

Garibaldi (TSX.V: GGI) Drills Into Bonanza Grades On 150-meter Step-out From Silver Eagle Discovery Hole

TSX Mining News: Garibaldi (TSX.V: GGI) Drills Into Bonanza Grades On 150-meter Step-out From Silver Eagle Discovery Hole

2.5-km Long Structural Zone Links Silver Eagle and Reales Targets

Vancouver, British Columbia - March 6, 2015 (Investorideas.com Mining stocks newswire) Garibaldi Resources Corp. (TSX.V: GGI) (the "Company" or "Garibaldi") is pleased to report that a combination of ongoing Phase 2 drilling and surface exploration continues to expand the scale of the Rodadero Silver-Gold Project in Sonora State, Mexico, with multiple high-grade drill intercepts, two linked targets and new target areas.

As the Phase 2 drill program continues, the latest highlights include:
·        SE-14-15, collared 150 meters north of Silver Eagle discovery hole SE-14-01 (the furthest step-out to date), has returned a shallow exceptional intercept of 1,307 g/tAg (42 oz/ton) over 1.5 meters within a broader interval of 6 meters (19.8 feet) grading 346 g/t Ag (11.1 oz/ton);
·        The Silver Eagle discovery is now confirmed to be structurally linked with the adjoining Reales target to the south to form the newly-named "SR High-Grade Zone” with a potential strike length in excess of 2 km;
·        A total of 12 silver-gold mineralized centers (Silver Eagle is the first one to be drilled) have now been outlined at Rodadero over 50 sq. km after the identification through surface sampling of a distinct east-west trending system more than 4 km north of Silver Eagle.

Dr. Craig Gibson, Ph.D., Msc., CPG, a director of Garibaldi and a renowned exploration expert who has been involved in several major discoveries in Mexico, commented: "Increasingly at Rodadero we are seeing the near-surface expression of what appears to be a very large system with perhaps multiple overprinting events. Mineralization is open laterally in all directions. What’s also exciting is the potential at depth - we’ve yet to drill below 100 meters where we would expect to discover the feeder zones which often exist in a system such as this. Deeper holes are coming.

"Approximately 70% of the drill holes at Silver Eagle have successfully intersected high-grade mineralization within just 50 meters of surface, a remarkable start at this target. Excitingly, we’re still in the early stages of exploration at this project,” Gibson stated.

Moving Forward At Rodadero
Key priorities as the Phase 2 drill program continues:
·        Additional drilling at Silver Eagle and initial drilling at Reales aimed at building potential near-term surface tonnage within the SR High-Grade Zone;
·        Testing of gold-rich drill targets to the east of Silver Eagle, specifically Tarichi and La Tortuga;
·        Testing of a new vein system mapped over the northern tip of Rodadero, an apparent extension onto Garibaldi ground from a former producing mine more than 4 km north of Silver Eagle.

Silver Eagle Discovery
Results for 15 drill holes at Silver Eagle confirm the geometry of this deposit target as a nearly flat lying tabular mineralized body. Most holes have produced significant silver values, and higher grades at Silver Eagle appear to have formed near a crosscutting fault that generally trends northerly and has been mapped for about 750 meters along strike.

The SR High-Grade Zone - Silver Eagle, Reales Targets
Significantly, after an extensive review of data, Company geologists and technical advisers now believe that the Silver Eagle and Reales targets along the western side of Rodadero are indeed linked as part of a north-northwest trending structural zone extending for at least 2.5 km.

Mineralization at Silver Eagle is hosted in silicified conglomerate and overlying andesitic volcanic rocks, while mineralization at Reales is hosted by limestone that underlies the conglomerate as well as andesitic volcanic rocks. The continuing drill program will include a series of holes at Reales in an attempt to confirm high-grade surface samples and extend the mineralized body to the south.

"These latest results from Rodadeo demonstrate that this is indeed an important new mineral camp discovery in central Sonora State,” commented Steve Regoci, Garibaldi President and CEO.

"Between Rodadero and our La Patilla Gold Project, we are uniquely positioned to capture more value for Garibaldi in Mexico. With the strategic initiatives we’re executing in Mexico, combined with the fully funded British Columbia exploration programs already under way in the prolific Sheslay district in preparation for first-ever drilling there, 2015 is shaping up to be a very exciting and rewarding year for our shareholders. We’re into a period of accelerated news flow,” Regoci concluded.

Significant Assay Results – Silver Eagle Discovery (Phase 2 Drilling)


Above widths are downhole core lengths and true widths are estimated at approximately 80%. Results for holes SE-14-01 to SE-14-06 were previously published in a news release Aug. 5, 2014. Holes SE-14-05 and SE-14-10 contained no significant values. *Holes SE-14-02 and 2A experienced technical issues and were stopped short; only 2B was completed to the target depth.

Silver Eagle Phase 2 Drilling Details
As reported November 26, 2014, recent sampling extended high-grade silver mineralization 150 meters north of discovery hole SE-14-01 along the fault zone referred to in this news release. This area was drill tested by SE-14-15 to explore the Silver Eagle system in a northerly direction, and it cut 6 meters of 346 g/t Ag. Included in that section is an interval of 1.5 meters grading 1,307 g/t Ag, 0.34 g/t Au, 0.60% Cu, 9.0% Zn and 0.90% Pb.

Drill holes SE-14-14 and SE-14-13 were drilled at the southernmost part of the main Silver Eagle mineralized body as exposed at the surface. Hole SE-14-14 was drilled under hole SE-14-06 and cut 3 meters of 250 g/t Ag. Hole SE-14-13 was drilled about 10 meters south of hole SE-14-06 and cut a near-surface interval of 1.7 meters with 31.3 g/t Ag. This hole was possibly stopped short of the main target.

Holes SE-14-09 to SE-14-12 were drilled to the west of the main mineralized structure with the high-grade silver intercepts reported previously to test the hypothesis that silver mineralization may also be stratigraphically controlled within the tabular silicified zone.

These holes generally encountered lower silver grades, but in some cases over significant widths. These holes indicate the possibility for a larger bulk tonnage target in addition to the high-grade target identified previously. Hole SE-14-12a was core recovered from the anchor that was drilled to stabilize the rig while drilling hole SE-14-12. This sample was 1 meter in length and assayed 1,352 g/t Ag, 3.4% Pb, 0.13 g/t Au, 0.50% Cu and 0.60% Zn.

Holes SE-14-07 and SE-14-08 were drilled to test areas adjacent to the high-grade mineralization found previously, and both holes intersected the high-grade system. Hole SE-14-07 was drilled between holes SE-14-01, SE-14-04 and SE-14-05, while SE-14-08 was drilled under SE-14-02, 02a and 02b and returned a wider intercept of 14.95 meters grading 155 g/t Ag.

Rodadero Exploration Update
Surface exploration has confirmed that a previously known and large east-northeast, west-southwest trending vein system near the northern edge of Rodadero, exploited in the past, extends onto ground held by Garibaldi. Past production along this vein system was significant as old mine workings with large dumps are present along with mill tailings.
Two targets, one at each extreme, have been identified and they are now referred to as El Rey and Dolores. They are approximately 2 km apart and replace the previous name of La Guata for the general area. An update on the El Rey and Dolores targets will be provided shortly.

Rodadero Video
To view a 2-minute Garibaldi video on the Rodadero discovery, please visit the homepage of GaribaldiResources.com or the following URL:
http://www.garibaldiresources.com/s/Media.asp#Rodadero

Quality Assurance & Control
Garibaldi maintains strict QA-QC protocols for all aspects of its exploration programs that include the systematic insertion of blanks and standards into each sample batch. Acme Labs (now part of the Bureau Veritis group that includes BSI Inspectorate) has performed assay analyses on Rodadero drill core and some of the rock samples, while ALS Global (formerly ALS Chemex) has also performed some analyses on rock samples. All samples reported in this release were assayed using certified and industry standard assay techniques for gold, and multi-element packages for other elements and for over-limits. Au was analyzed by 30 to 50 gram fire assay with an atomic absorption finish, and other elements were analyzed by multi-element ICP.

Qualified Person
Dr. Craig Gibson, Certified Professional Geologist and a director of Garibaldi, is a non-arms-length Qualified Person for the Company’s Mexico projects and the direct manager of the technical programs operated under contract by Prospeccion Y Desorrollo Minera del Norte (ProDeMin). Dr. Gibson has reviewed this news release and approved the contents thereof.


About Garibaldi
Garibaldi Resources Corp. is an active Canadian-based junior exploration company focused on creating shareholder value through discoveries and strategic development of its assets in some of the most prolific mining regions in Mexico and British Columbia.

We seek safe harbor.

GARIBALDI RESOURCES CORP.
Per: "Steve Regoci"
Steve Regoci, President

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or the accuracy of this release.

This news is published on the Investorideas.com Newswire and its syndicated partner network


Get Free investor news and stock alerts: Sign up here

Published at the Investorideas.com Newswire - Big ideas for Global Investors

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp The following is a paid for news release.
Disclosure : GGI NEWS RELEASE was paid for publishing by third party ($75)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.




Thursday, February 26, 2015

TSX Mining News: Garibaldi (TSX.V: GGI) Signs LOI To Send La Patilla Mill Feed To Gainey Capital's Processing Facility

TSX Mining News: Garibaldi (TSX.V: GGI) Signs LOI To Send La Patilla Mill Feed To Gainey Capital's Processing Facility

Vancouver, British Columbia - February 26, 2015 (Investorideas.com Mining stocks newswire) Garibaldi Resources Corp. (TSX.V: GGI) (the "Company" or "Garibaldi") is pleased to announce that it has signed a Letter of Intent (“LOI”) with Gainey Capital Corp. (TSX.V: GNC) to initiate an immediate program to deliver mineralized material from the Company’s La Patilla Gold Property in Sinaloa State, Mexico, to Gainey’s 300 tpd processing facility just 40 miles to the southeast.

This LOI marks another important step for Garibaldi at La Patilla where the Company's strategic plan since acquiring this asset in 2013 has been to move to the exploitation stage as quickly as possible to generate cash flow.

Artisanal miners have been active at La Patilla for decades, the Company has negotiated a long-term agreement with the local community to allow for exploitation at this property, and a highly successful drill program in early 2014 confirmed the presence of near-surface mineralization including 8.5 g/t Au over 10.4 meters within a broader interval of 3.1 g/t Au over 30 meters in diamond drill hole LP-14. La Patilla is considered very prospective for high-grade "shoots".

Garibaldi and Gainey will use this LOI as a framework for a potential long-term revenue sharing agreement between the two companies. In addition, the processing of mineralized material from La Patilla will provide Garibaldi with important additional metallurgical and grade information to further assess the exploitative potential of this asset. Preliminary La Patilla metallurgical testing by Garibaldi has produced encouraging results.

"Our team in Mexico was very impressed with Gainey's state-of-the-art gravimetric/flotation processing center," commented Steve Regoci, Garibaldi President and CEO. "This should be an excellent fit for advancing La Patilla which importantly is located just a short distance away."

Investors are cautioned that the planned processing of mineralized material from La Patilla is not based on a National Instrument 43-101 mineral resource or reserve estimate, preliminary economic assessment, prefeasibility study or feasibility study. As a result, there is no assurance that Garibaldi will be able to economically extract mineralization from La Patilla.

Rodadero Update
Garibaldi eagerly anticipates updating shareholders with regard to the latest exploration developments including assay results from ongoing work at Rodadero, its Mexican flagship project, during the week of March 2, 2015.

Recent corporate developments, including a Rodadero site visit by a second leading producer, and the recently announced bid for Paramount Gold and Silver Corp. by Coeur Mining Inc., have required management to weigh competing strategies to ensure maximum value for shareholders.

Garibaldi values and appreciates its shareholders' loyalty and patience as the Company continues to work toward a breakthrough year in both Mexico and British Columbia.

Garibaldi at PDAC
Garibaldi invites shareholders and interested investors to visit the Company's booth (#3153) and meet with management at PDAC, Sunday, March 1 through Wednesday, March 4, at the Toronto Convention Centre. Drill core from Rodadero will be on display.


Qualified Person
Dr. Craig Gibson, Certified professional Geologist and a director of Garibaldi is a non-arms-length Qualified Person for the Company's Mexico projects and a direct manager of the technical programs operated under contract by Prospeccion Y Desorrollo Minera del Norte (ProDeMin). Dr. Gibson has reviewed this news release and approved the content thereof.

About Garibaldi
Garibaldi Resources Corp. is an active Canadian-based junior exploration company focused on creating shareholder value through discoveries and strategic development of its assets in some of the most prolific mining regions in Mexico and British Columbia.

We seek safe harbor.

GARIBALDI RESOURCES CORP.
Per: "Steve Regoci"
Steve Regoci, President

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or the accuracy of this release.

This news is published on the Investorideas.com Newswire and its syndicated partner network


Get Free investor news and stock alerts: Sign up here

Published at the Investorideas.com Newswire - Big ideas for Global Investors

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp The following is a paid for news release.
Disclosure : GGI NEWS RELEASE was paid for publishing by third party ($75)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.



Tuesday, January 21, 2014

Penny Stock Trading Alert; TSX Biotech Stock: Q&A Interview with CEO of Quest PharmaTech (TSX.V: QPT)

New York NY - Point Roberts WA - January 21, 2014 (Investorideas.com Newswire) Investorideas.com, a global news source for leading sectors including biotech and pharma issues an exclusive interview with Dr. Madi R. Madiyalakan, Ph.D., Chief Executive Officer of Quest PharmaTech Inc. (TSX.V: QPT). Dr. Madiyalakan shares insight into the Company’s pipeline of oncology products. The Company takes a unique approach to cancer treatment that capitalizes on the recent major advances in the understanding of immune physiology and developing proprietary next generation cancer immunotherapy treatments using select antibodies, adjuvants and photosensitizers.

Interview:
Q: Investorideas.com
For readers unfamiliar with your company, can you give a brief introduction on your background in the biotech space and the formation of Quest PharmaTech?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
I have been involved in the Biotech industry for over 27 years, first as a scientist at Biomira Inc (now known as Oncothyreon) and then as a founding executive team member of several biotech companies including, AltaRex Corp., CanBiocin Inc. and SonoLight Pharmaceuticals Corp. My relationship with Quest began when Quest PharmaTech acquired SonoLight Pharmaceuticals in 2001. That acquisition provided a path forward for technology I had invented and championed ([Dr. Madiyalakan holds 10 primary U.S. patents and eight pending patents]). I have been instrumental in raising more than $200 million through private placement and public offerings for those companies. I specialize in advancing novel technologies with great therapeutic potential in areas of unmet medical need.
Quest was started as a research and development company in 1998 and was listed on the TSX Venture Exchange in 1999. I have been CEO of the Company since 2006.
Q: Investorideas.com
Can you briefly describe the current product portfolio and the primary oncology focus for each?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Our technology is focused on the immunotherapy of cancer. We utilize tumor directed monoclonal antibodies to activate the specific immunity; however we recognize that successful therapy requires orchestrated combination with chemotherapy, photodynamic therapy and select additional immune modulators or adjuvants. Our lead product, Oregovomab, which is currently completing a phase II clinical trial in both Italy and the U.S., is used in combination with standard chemotherapy in ovarian cancer patients. It is also being tested in combination with other immunotherapeutic agents for use in treating pancreatic cancer patients. Our pipeline also includes proprietary antibodies against other cancer markers, most notably MUC1, PSA and HER2. We expect to advance our MUC1 targeting antibody into the clinic in the coming year. MUC1 expressing cancers include many commonly occurring solid cancers such as breast, pancreatic and lung cancers.
We are also very excited about our new pipeline of therapeutic IgE antibodies, which we recently acquired from Advanced Immune Therapeutics, Inc. and for which we obtained license rights from UCLA and Stanford University. In addition to their immunotherapeutic potential, these molecules also have the potential to act in the tumor micro-environment to augment the effectiveness of chemotherapy. We truly believe that the IgE technology will be a breakthrough for the treatment of cancer.
Q: Investorideas.com
Can you discuss the current status of your flagship product OREGOVOMAB and its applications in immune therapy?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Quest's proprietary approach uses antibodies to modulate and enhance specific immunity to the target tumor antigen and associated tumor. Recent insights into the ability of cytotoxic therapy to enhance immunity, and the development of novel adjuvant approaches, suggests that a simple and artful approach using a combination of components for specific cancer immunotherapy can change the clinical course of cancer. We are using our lead product Oregovomab as an example to demonstrate the proof of concept for the combinatorial immunotherapeutic approach and trying to identify ideal combinations by conducting three different clinical trials. The most advanced of these is an 80 patient phase II clinical trial in advanced ovarian cancer patients that is being conducted in 13 clinical centers in Italy and the U.S. We hope the results from this trial will confirm the findings in an earlier study that shows combining chemotherapy with Oregovomab leads to the generation of specific anti-cancer T-cells and the potential for clinical benefits. We are also conducting another clinical trial in the U.S. using Oregovomab in combination with another chemotherapeutic agent, Gemcitabine, together with radiation therapy for treating pancreatic cancer. The trial will help us to expand the market opportunities for Oregovomab to other CA125 expressing cancers as well as to evaluate immunotherapy in combination with chemo radiotherapy. We are also looking at the addition of an immunoadjuvant, Hiltonol, a TLR3 agonist, which we have licensed from a U.S based company, Oncovir, to further augment the immune response. The completion of these 3 clinical trials will provide us with the roadmap for commercialization of this product. To summarize, Quest's approach has created an opportunity to mobilize immunity, better, more precisely and for less cost than other methods that are in development, and, or, recently approved.
Q: Investorideas.com
Can you give us some background on the key members of your team and the scientific board and the expertise they bring to the company?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Working with me on themanagement team, I have Thomas Woo, Vice President of Product Development since 2002. Thomas honed his drug development skills at Biomira, AltaRex and Cytovax. My CFO, Pierre Vermette, comes with extensive experience gained at the Alberta Securities Commission and has been with the Company since 2003.
On theBoard of Directors, I have Lorne Meikle, our Chairman, Ian McConnan, our Audit Committee Chair and Paul Van Damme, our Corporate Governance Chair.
Mr. Meikle has an extensive background in the life sciences area, Mr. McConnan is a former partner of several public accounting firms, and Mr. Van Damme has acted in the CFO role for a number of public and private companies.
On the Company's Scientific Advisory Board, I have internationally known scientists who occupy important positions in various institutions around the world. Dr. Samuel Abraham, Ph.D., is the Vice President of Research with the British Columbia Cancer Agency. Professor Ki-Jun Hwang is a well respected medicinal chemist at Chonbuk University in South Korea. One of the clinicians, Dr. Ronald Moore, who is developing a unique treatment for prostate cancer at the Cross Cancer Institute in Canada, is also one of our scientific advisory board members. Dr. Moore, along with Dr. Gerald Miller in Australia, provide a strong scientific direction to our photodynamic therapy program.
On the Company's Clinical Advisory Board (CAB), I have Dr. Christopher Nicodemus, a clinical expert in tumor immunology and drug development who has been championing the combinatorial immunotherapeutic approach supported by numerous publications and patents. He relies on the advice of his fellow CAB members, key opinion leaders such as Professor William McGuire in the U.S, Professor Ignace Vergote in Belgium and Dr. Thomas Ehlen in Canada.
All members of the CAB have a keen interest in innovative improvements in the area of ovarian cancer and see a great opportunity to advance the previous learning with Oregovomab in the context of combination therapies that will better access the immune response and limit immune suppression that has impeded earlier efforts to vaccinate against cancer.
Q: Investorideas.com
Can you share with readers the significance of some of your key relationships including Stanford University and UCLA?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Significance of Key Relationships:
We are very pleased to be licensing IgE technologies developed by the distinguished scientists from these prestigious institutions. In addition, we are also working closely with the Eppley Cancer Institute at the University of Nebraska to develop animal models and complete pre-clinical testing of potential drug candidates.
Q: Investorideas.com
With all biotech companies, funding is a key factor to success; last November you announced a $1million placement for Quest PharmaTech. C an you explain the significance of this round of financing and where this takes you to?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
We wanted to strengthen our relationship with our long term investment partner, AD Biotech Co., Ltd. AD Biotech has committed $12 Million to fund our ongoing clinical programs during the next two years. We were pleased with their confidence in Quest as demonstrated by their investment of $1 Million at a premium share price.
Q: Investorideas.com
In closing what are some of the key milestones for 2014 for Quest PharmaTech?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Some of the key 2014 milestones we hope to achieve in the coming year include completing patient enrollment of the Oregovomab clinical trial and obtaining preliminary data for the Oregovomab clinical trial in Italy and US; initiating a clinical study combining Oregovomab with immuno-adjuvants; expanding the Company's opportunities for revenue generation through product sales of some evidence based over-the-counter nutraceutical and cosmetic products licensed from our joint venture partner; generating critical additional data demonstrating the therapeutic potential of our proprietary IgE portfolio; and, pursuing out-licensing arrangements as a source of additional revenue and validation for our technologies.
About Quest PharmaTech Inc.:
Quest PharmaTech Inc. (Quest) is a publicly traded (TSX Venture), Alberta-based biotechnology company committed to the development and commercialization of oncology product candidates. It is developing a series of products for the treatment of cancer based on its pipeline of SonoLight compounds, and monoclonal antibodies that target certain tumor antigens that are presented in a variety of cancers. Quest believes that by combining these antibodies with other cancer therapies such as chemotherapy or photodynamic therapy, it can potentially further complement and enhance treatment outcomes compared to antibody treatment alone. http://www.questpharmatech.com/
About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy and Latin American stocks.
Sign up for our free news alerts
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: QPT.V, a public company, has engaged Investorideas.com for public relations services for four thousand a month retainer fee.
More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Global investors must adhere to regulations of each country.
800-665-0411 - Source - www.Investorideas.com

Monday, December 16, 2013

Penny Stock Trading Alert; Solar Stock XsunX (OTCQB: XSNX) Announces Sales and Building Momentum Into 2014

ALISO VIEJO, CA - December 16, 2013 (Investorideas.com renewable energy newswire) XsunX, Inc. (OTCQB: XSNX), a renewable energy technology, systems, and services company, today announced adding 50kW in signed projects to its growing PV system development and installation services pipeline. The Company is focused on signing more solar contracts before year end.

"We are very excited about the rapid progress we have been making, and announcing 50kW in new projects just adds to our momentum," stated XsunX CEO, Tom Djokovich.
The Company has been working to develop solar projects for a diverse set of clients ranging from professional service companies, to ranch land, to large scale industrial reclamation. The Company has been working directly with new business clients to document the financial benefits available from solar for their businesses.
To help expand and accelerate the growth of the Company's PV system development and installation services business, XsunX has launched a media marketing campaign which targets major Southern California communities ranging from Ventura to the Inland Empire, LA, Orange County and portions of San Diego county. This market represents one of the largest commercial PV system markets in the country and thousands of potential commercial PV system clients for XsunX.
"The message and the reality is that solar has become far more than just a way to cut utility costs. A commercial PV system can provide clients with a 100% cash value return on their investment in as little as three years, and well in excess of a 1000% return on every dollar invested over the life of the system," concluded Mr. Djokovich.
About XsunX
XsunX focuses on providing solar energy solutions that provide the greatest bottom-line financial benefits. The Company's background and experience spans virtually all aspects of solar including technology assessment, design, and development. We have a deep passion for solar and have worked to pioneer new technologies and solar business solutions focused at making solar an affordable energy option. For more information, please visit the Company's website at www.xsunx.com.
Safe Harbor Statement
Matters discussed in this release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein, are included in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Contact:
Tom Djokovich
President and CEO
949-330-8060
info@xsunx.com
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by XSNX for news distribution averaging 1500 per month. http://www.investorideas.com/About/Disclaimer.asp